CN Patent

CN107427007B — 用于治疗水肿的组合物和方法

Assigned to Memorial Sloan Kettering Cancer Center · Expires 2022-02-11 · 4y expired

What this patent protects

提供了使用抗T细胞剂、抗TGF‑β1剂或抗血管紧张肽剂，优选地至少两种此类药剂的组合治疗或预防水肿的药物组合物和方法。所述药物组合物可以被配制用于全身或局部施用，并且优选地局部施用。

USPTO Abstract

提供了使用抗T细胞剂、抗TGF‑β1剂或抗血管紧张肽剂，优选地至少两种此类药剂的组合治疗或预防水肿的药物组合物和方法。所述药物组合物可以被配制用于全身或局部施用，并且优选地局部施用。

Drugs covered by this patent

Patent Metadata

Patent number: CN107427007B
Jurisdiction: CN
Classification: —
Expires: 2022-02-11
Drug substance claim: No
Drug product claim: No
Assignee: Memorial Sloan Kettering Cancer Center
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.